This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-effectiveness analysis, cost-benefit analysis
Study objective
The objective was to assess the long-term outcomes and costs of a continued standard care strategy versus a simple strategy of atazanavir-ritonavir alone, in human immunodeficiency virus (HIV) patients who had achieved suppression of the HIV ribonucleic acid level while receiving treatment.
Interventions
In the standard care strategy, patients received five sequential regimens of combination antiretroviral therapy. Initially they received a non-nucleoside reverse transcriptase inhibitor regimen, followed by two ritonavir-boosted, protease inhibitor (PI) regimens, then a regimen containing ritonavir-boosted darunavir, with or without enfuvirtide, and finally a minimally effective salvage regimen, which did not include enfuvirtide.
In the simple strategy, all patients were switched from their current suppressive therapy, at the start of the study, to a simple maintenance regimen consisting of atazanavir-ritonavir.
Location/setting
USA/the setting was not reported.
Methods

Analytical approach:
A state-transition model (the Cost-Effectiveness of Preventing AIDS Complications model) was used to project the health outcomes and costs of the two interventions. A lifetime horizon was used and the authors stated that a population perspective was adopted.
Effectiveness data:
The effectiveness data came from published studies. The authors did not report any search methods or inclusion criteria. The main clinical parameters were the efficacy and adverse events of a sequence of HIV drug regimens.
Monetary benefit and utility valuations:
Not reported.
Measure of benefit:
The two measures of benefit were life expectancy and quality-adjusted life expectancy (QALE). The future benefits
